endra life sciences inc - NDRA

NDRA

Close Chg Chg %
5.17 0.10 1.93%

Pre-Market

5.27

+0.10 (1.93%)

Volume: 9.08K

Last Updated:

Apr 9, 2026, 4:00 PM EDT

Company Overview: endra life sciences inc - NDRA

NDRA Key Data

Open

$5.06

Day Range

5.06 - 5.31

52 Week Range

2.90 - 11.96

Market Cap

$6.41M

Shares Outstanding

1.24M

Public Float

650.22K

Beta

-0.22

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$8.91

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

65.34K

 

NDRA Performance

1 Week
 
13.22%
 
1 Month
 
53.03%
 
3 Months
 
14.19%
 
1 Year
 
44.29%
 
5 Years
 
-99.99%
 

NDRA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About endra life sciences inc - NDRA

ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

NDRA At a Glance

ENDRA Life Sciences, Inc.
3600 Green Court
Ann Arbor, Michigan 48105-1570
Phone 1-734-335-0468 Revenue 0.00
Industry Medical Specialties Net Income -7,027,410.00
Sector Health Technology Employees 11
Fiscal Year-end 12 / 2026
View SEC Filings

NDRA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.358
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.588
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.149

NDRA Efficiency

Revenue/Employee N/A
Income Per Employee -638,855.455
Receivables Turnover N/A
Total Asset Turnover N/A

NDRA Liquidity

Current Ratio 1.289
Quick Ratio 1.289
Cash Ratio 1.015

NDRA Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -169.21
Return on Equity -291.564
Return on Total Capital -255.313
Return on Invested Capital -247.839

NDRA Capital Structure

Total Debt to Total Equity 21.784
Total Debt to Total Capital 17.888
Total Debt to Total Assets 12.776
Long-Term Debt to Equity 16.06
Long-Term Debt to Total Capital 13.187
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Endra Life Sciences Inc - NDRA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
234.26K 275.45K 206.17K 157.29K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
234.26K 275.45K 206.17K 157.29K
Depreciation
234.26K 275.45K 206.17K 157.29K
Amortization of Intangibles
- - - -
-
COGS Growth
+4.39% +17.58% -25.15% -23.71%
Gross Income
(234.26K) (275.45K) (206.17K) (157.29K)
Gross Income Growth
-4.39% -17.58% +25.15% +23.71%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
12.92M 10.25M 10.61M 5.61M
Research & Development
6.55M 5.00M 3.19M 1.85M
Other SG&A
6.37M 5.24M 7.42M 3.76M
SGA Growth
+14.63% -20.72% +3.57% -47.17%
Other Operating Expense
- - - 7.32M
-
Unusual Expense
- - (3.08M) 1.66M
-
EBIT after Unusual Expense
(13.16M) (10.52M) (15.06M) (7.42M)
Non Operating Income/Expense
(21.53K) 460.48K 3.56M 395.88K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(13.18M) (10.06M) (11.51M) (7.03M)
Pretax Income Growth
-17.34% +23.67% -14.39% +38.93%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.18M) (10.06M) (11.51M) (7.03M)
Minority Interest Expense
- - - -
-
Net Income
(13.18M) (10.06M) (11.51M) (7.03M)
Net Income Growth
-17.34% +23.67% -14.39% +38.93%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.18M) (10.06M) (11.51M) (7.03M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.18M) (10.06M) (11.51M) (7.03M)
EPS (Basic)
-7976.85 -2766.5225 -56.9402 -8.9291
EPS (Basic) Growth
+17.84% +65.32% +97.94% +84.32%
Basic Shares Outstanding
1.65K 3.64K 202.11K 787.02K
EPS (Diluted)
-7976.85 -2766.5225 -56.9402 -8.9291
EPS (Diluted) Growth
+17.84% +65.32% +97.94% +84.32%
Diluted Shares Outstanding
1.65K 3.64K 202.11K 787.02K
EBITDA
(12.92M) (10.25M) (17.93M) (5.61M)
EBITDA Growth
-14.63% +20.72% -75.05% +68.74%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 30.00
Number of Ratings 1 Current Quarters Estimate -1.14
FY Report Date 06 / 2026 Current Year's Estimate -4.65
Last Quarter’s Earnings -1.23 Median PE on CY Estimate N/A
Year Ago Earnings -8.93 Next Fiscal Year Estimate -4.00
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 1
Mean Estimate -1.14 -1.14 -4.65 -4.00
High Estimates -1.14 -1.14 -4.65 -4.00
Low Estimate -1.14 -1.14 -4.65 -4.00
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Endra Life Sciences Inc in the News